• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BD launches automated infectious disease diagnostic platform in the U.S.

BD launches automated infectious disease diagnostic platform in the U.S.

May 12, 2022 By Sean Whooley

BD COR MX PX
[Image from BD]
BD (NYSE:BDX) announced today that it began the U.S. launch of its new, fully automated, high-throughput diagnostic platform.

Franklin Lakes, New Jersey-based BD designed the BD COR MX instrument option, which now has FDA 510(k) clearance, for molecular diagnostics for infectious disease.

According to a news release, the first test available on the instrument option for the BD COR system is the BD CTGCTV2 molecular assay — a single test for detecting three sexually transmitted infections (STIs): Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV).

BD COR MX/PX integrates and automates the complete molecular laboratory workflow from sample processing to diagnostic results for high throughput labs, the company said. According to BD, the platform eliminates the need to sort specimens, giving lab techs the ability to have very little interaction with the specimen and free up time for other lab processes.

In total the BD COR MX/PX system allows for the loading of 1,700 specimens, with onboard capacity for reagents and samples providing more than seven hours of unimpeded system processing. The company said it can deliver up to 1,000 sample results in 24 hours and offers dual DNA targets for CT and GC detection in the same sample and assay to reduce false positives.

Collection options for the assay include self-collection in a clinical setting, vaginal/endocervical swab, urine (both male and female) and liquid-based cytology.

BD COR also includes a GX instrument that uses the BD Onclarity HPV assay with extended genotyping for HPV infections. The company is developing more assays for the MX instrument that range beyond women’s health and STI testing.

“Even before COVID-19, clinicians and laboratory technicians were faced with increasing workloads and patient needs, and now those challenges have been amplified significantly by the ongoing staffing shortages and further increased workloads caused by the pandemic,” President of Integrated Diagnostic Solutions Brooke Story said in the release. “By automating labor-intensive and mundane error-prone processes, the BD COR MX/PX system allows lab technicians and clinicians to focus on higher value work.”

The announcement comes a day after the company announced the expansion of a strategic partnership with Babson Diagnostics to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics Tagged With: BD

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy